Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Briacell Therapeutics Corp T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


TSX:BCT - Post by User

Comment by Silky_Johnsonon Feb 25, 2021 11:54am
174 Views
Post# 32658358

RE:RE:RE:RE:Yea it is a gift

RE:RE:RE:RE:Yea it is a gift

I agree with this statement. One thing we must consider is what the alternative was...$0  


At the end of the day, a company with a $3 million market cap raised $25 million and is now funded through to a registration study. They will now be able to dose a bunch of patients in combination with Keytruda and Incyte's drug. 


it will be a bumpy road for a few weeks for sure. I just hope that they can mimic past results with a larger group size and perhaps start their OTS treatment. If they can demonstrate efficacy on a larger scale this will still be a big win.

they have been out of money for 18 months so it's at least a good thing that the lights are on and we can get back to doing what we did before. 

$10 share price is )120 million market cap. These plays on the Nasdaq can easily float up to the $500 mill-$ 1 Bill valuation on a catalyst which is very possible here. 


ive been around this name for many years now. Did some tax loss selling in dec but am back on the buy side now to take advantage of the current market mispricing. Clients sell the shares and keep the warrants or sell the warrants to lower cost base of the shares...why we see it trading below IPO price. It will take a bit of time to churn this out but it will happen. 


Cheers,
Silky
 

<< Previous
Bullboard Posts
Next >>